Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

Actavis Receives FDA Approval of Zolpidem Tartrate Extended-Release Tablets

By Pharmaceutical Processing | June 7, 2011

 

Actavis has received final approval from the FDA to market
Zolpidem Tartrate Extended-Release Tablets USP, 12.5 mg CIV.

 

Distribution of the product has commenced.

 

Actavis was the first company to launch Zolpidem Tartrate Extended-Release
Tablets 6.25 mg strength in October 2010 with 180-day exclusivity.

 

Zolpidem Tartrate Extended-Release Tablets, the generic
equivalent of Ambien CR , had US
sales of approximately $793 million for the 12 months ending March 31, 2011,
according to IMS Health.

 

Commenting on the new approval, Doug Boothe, CEO of Actavis
in the US,
said: “The approval of Zolpidem ER Tablets 12.5 mg enables Actavis to
offer both strengths to meet the needs of our customers. This approval also underscores
Actavis’ emphasis and commitment to bringing complex controlled-release
products to the marketplace to help improve patient access to pharmaceuticals.”
 

 

Related Articles Read More >

Glass vials moving through the filling station of a Flexicon liquid filling machine
How local regulations are becoming global pharma manufacturing standards 
AI in clinical trials: practical uses and limits
A photo of Fujifilm Biotechnologies' Holly Springs, North Carolina, facility.
Fujifilm Biotechnologies selected for FDA PreCheck Pilot Program
Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE